Portugal Emerging as a Global Hub for Healthcare MedTech and Biotech Investments with Unique Golden Visa Residency Opportunities

Portugal is emerging as a hub for impactful investments in healthcare and cutting-edge sectors like MedTech and Biotech, offering unique opportunities for those seeking residency through the Golden Visa programme.

With a highly rated healthcare infrastructure, Portugal has achieved notable progress in health performance, reflected in its life expectancy of 83 years in 2024, surpassing the Eurozone and the United States. This accomplishment stems from a robust public-private collaboration, ensuring efficient resource utilization and superior healthcare delivery.

The country boasts a dynamic ecosystem of MedTech and Biotech start-ups specializing in AI-driven diagnostics, telemedicine, and health data solutions. For instance, Sword Health, a pioneer in digital musculoskeletal therapy, has garnered international acclaim.

Additionally, Biovance Capital, a €51 million biotech-focused fund, supports early-stage biopharma companies across Europe, with a strong emphasis on Portugal. The fund’s strategic investments highlight the country's growing prominence in the global healthcare landscape.

In 2024, Partners Group acquired a majority stake in FairJourney Biologics, a biotech company based in Portugal, valued at approximately €900 million. This marked a significant milestone for the industry, showcasing the country’s potential for lucrative investments.

Portugal is also experiencing a surge in medical tourism, with procedures like cosmetic surgery, dental treatments, orthopaedic surgeries, and fertility treatments in high demand. Government initiatives and partnerships with private healthcare providers have propelled the growth of this sector.

Portugal’s Golden Visa programme allows investors to commit a minimum of €500,000 to approved alternative investment funds, many of which focus on healthcare innovations. These investments often support advancements in medical technology, expansion of healthcare facilities, and development of biotech start-ups.

Golden Visa investors not only contribute to the development of Portugal̢۪s healthcare sector but also gain residency in Portugal with access to the European Schengen Area. The programme requires a minimal stay of just seven days annually and offers a pathway to permanent residency and EU citizenship after five years.

Healthcare investments aligned with the Golden Visa programme present a unique blend of financial returns and meaningful societal contributions. From expanding elderly care facilities to advancing telemedicine, these investments resonate with Portugal̢۪s vision of fostering innovation and improving quality of life.

Portugal̢۪s commitment to integrating innovation with high-quality healthcare creates an attractive opportunity for investors. The Golden Visa programme serves as a secure, impactful avenue for individuals seeking European residency while contributing to the evolution of a thriving industry.

By choosing healthcare-focused Golden Visa-approved funds, investors can achieve both financial growth and lasting contributions to society, solidifying Portugal̢۪s position as a global leader in healthcare innovation.